What Degenerative Joint Disease Actually Is in Dogs

The dog was a nine-year-old German shepherd mix named Otto, sixty-eight pounds, and his owner brought him in because he’d started “skipping” the third stair on the back deck every evening around dinnertime. Not falling. Not crying out. Just skipping it, the way a person avoids a floorboard that creaks. She’d noticed it for about six weeks. On exam, Otto had reduced range of motion in both hips, mild crepitus on the left stifle, and a gait that looked almost normal until you asked him to trot a figure-eight on the exam room tile. That’s the pattern I see more often than any other: not a limp, but an avoidance.

What “degenerative” means once you’re inside the joint

Degenerative joint disease, often shortened to DJD and used more or less interchangeably with osteoarthritis, describes a joint whose cartilage is breaking down faster than the body can repair it. Articular cartilage has no direct blood supply, so once it’s damaged, it heals slowly and imperfectly if it heals at all. The joint responds by remodeling bone at its margins, thickening the joint capsule, and changing the composition and volume of synovial fluid, which is the lubricant that lets cartilage surfaces glide instead of grind. According to Cornell University’s Cornell University College of Veterinary Medicine: Riney Canine Health Center, osteoarthritis affects at least 20% of dogs over one year old and as many as 80% of dogs over eight — a spread wide enough that age alone stops being a useful predictor and the exam has to do the work instead.

That’s the part owners underestimate. DJD is not a single event you can point to on a calendar. It is cumulative wear, usually set in motion years earlier by an unstable joint — hip dysplasia, a torn cruciate ligament, elbow dysplasia, an old fracture that healed slightly off-axis. The joint compensates for years before it starts sending an obvious signal, which is exactly why a dog can look “suddenly” stiff at nine when the process arguably started at three.

DJD, osteoarthritis, and arthritis — same disease, three doors

Clients ask me to sort these terms out constantly, and I understand why the overlap is confusing. In practice, degenerative joint disease and osteoarthritis refer to the same underlying process — progressive cartilage loss with secondary bony change — while “arthritis” is the broader umbrella that technically also covers inflammatory and infectious joint disease, which behave and respond to treatment very differently. When I use DJD in a medical record, I’m being specific: this joint is wearing down mechanically, not being attacked by an immune process or an infection. That distinction changes the workup. An immune-mediated polyarthritis calls for joint taps and bloodwork. A degenerative hip calls for a different set of questions entirely — how long, how far, on what surface, and whether pain shows up at rest or only after exertion.

Glucosamine and chondroitin are among the most studied joint support ingredients for dogs, and the mechanistic story behind them tracks with what’s happening at the cartilage surface in DJD. Chondroitin has been shown to support healthy synovial fluid homeostasis, according to a Frontiers in Veterinary Science review — relevant because degraded synovial fluid is part of what accelerates the grinding in a DJD joint, not just a downstream symptom of it. Separately, glucosamine HCl has been found to help prevent experimentally induced cartilage degradation in vitro, per a review in the Journal of Veterinary Medical Science. Neither claim tells you a supplement will reverse an established DJD joint — nothing does, structurally — but they describe plausible mechanisms for slowing the pace of further breakdown, which is a realistic goal once cartilage loss has already started. Owners weighing a glucosamine-versus-MSM decision, or considering alternatives to glucosamine altogether, are really asking which mechanism fits their dog’s stage of disease, not which product has the loudest label.

The imaging question: when a radiograph confirms and when it misleads

Here is where I part ways with clinicians who treat radiographs as the final word. Imaging matters. A well-positioned hip or stifle film can confirm bony remodeling, joint space narrowing, and osteophyte formation that support a DJD diagnosis, and it rules out things that mimic it — a bone tumor, a subtle fracture, an infected joint. I order films readily, and I’d rather have one and not need it than guess. But joint pain on palpation and radiographic severity correlate poorly in dogs, which means a dog can have a joint that looks dramatic on film and moves comfortably, or a joint that looks unremarkable and hurts every time it bears weight after rest. The COAST staging framework, discussed by the American Animal Hospital Association, leans on that gap deliberately — treatment decisions are meant to follow the clinical exam and owner-reported function, with imaging used to confirm and exclude rather than to dictate the plan on its own.

That’s why I still reach for both the imaging study and the acupuncture needle in the same visit, and I don’t think that’s a contradiction. The film tells me what structural damage exists. The hands-on exam and a trial of acupuncture tell me how that damage is currently expressing itself as pain and restricted movement — which is the thing the owner actually lives with. A randomized, placebo-controlled trial published via PubMed evaluated acupuncture for pain associated with naturally occurring osteoarthritis in dogs, and it’s the kind of evidence I point skeptical colleagues toward, because it was designed to isolate a real effect rather than rely on anecdote. I don’t present acupuncture as a cure, and I wouldn’t tell an owner to skip radiographs in favor of it. I present it as a tool that may help support comfort in a joint whose structural fate has already been set by the time cartilage loss shows up on film.

I had a case a few years back — a lab-mix, mid-body, roughly eleven years old — whose owner had already been told by two other clinics that “nothing more could be done” beyond an NSAID. Her hips looked rough on the film, no argument there. But her actual limitation was a hunched, guarded posture over the lumbar spine that nobody had examined closely, layered on top of the hip changes. We treated both: continued the NSAID at the dosing her regular vet had set, added a structured acupuncture series, and reassessed her willingness to take stairs and jump into the car over the following weeks. I’m careful never to call that kind of outcome a success rate or a study result — it’s one dog, one exam room, and it doesn’t generalize. What it does illustrate is why I resist treating a radiograph as the whole diagnosis. The film explained her hips. It didn’t explain her posture, and it never would have on its own.

Where nutraceutical support and food therapy actually fit

Green-lipped mussel is the ingredient owners ask me about most after glucosamine and chondroitin, usually because they’ve seen it marketed as a “natural” anti-inflammatory. The evidence is real but narrower than the marketing suggests. In a rodent model, extracts including green-lipped mussel powder alleviated paw swelling and reduced serum markers of inflammation, including TNF-α and IL-17, according to a study in Nutrients. That’s a legitimate signal for an anti-inflammatory mechanism worth studying further in dogs, but it’s a paw-swelling model in rats, not a canine DJD trial, and I’m careful not to let owners round that up into more than it is.

Where I diverge from a strictly Western workup is in treating food and herbal therapy as part of the same conversation as imaging and pharmaceuticals, not as an alternative to them. A joint that’s mechanically degenerating benefits from weight control, appropriate omega-3 intake, and — in dogs whose constitution and presentation fit the pattern — food therapy principles drawn from traditional Chinese veterinary medicine, layered on top of, never instead of, a confirmed structural diagnosis. Dogs with DJD in a weight-bearing hind limb sometimes present with a gait that looks neurologic before it’s examined properly, which is worth ruling out early; I’d point an owner toward a checklist for telling joint pain from nerve damage before assuming stiffness is purely orthopedic.

The verdict

Degenerative joint disease in a dog is a mechanical, progressive, largely irreversible loss of cartilage with secondary bony change — not an inflammatory attack, not an infection, and not something a supplement label alone will diagnose or reverse. The evidence for glucosamine, chondroitin, and green-lipped mussel supports plausible mechanisms for slowing the process and easing its downstream inflammation; none of it supports cartilage regeneration. Imaging belongs in a real workup because it confirms structural change and rules out mimics, but it should not be the only lens an owner or clinician looks through, since pain and radiographic severity don’t reliably track together. My own bias, stated plainly, is to run the film and still put a needle in the dog if the exam supports it — the two tools answer different questions, and a DJD diagnosis usually needs both answered. Owners comparing supplement options against that evidence base may find our panel’s scored breakdown of the best joint supplements for dogs useful for sorting label claims from mechanism.

Is a stiff third stair ever “just age,” or is it the first data point in a much longer file?